Health-related quality of life and survival of patients with hepatocellular carcinoma treated with transarterial chemoembolization and Yttrium-90
Abstract Background Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Due to the advanced stage in which HCC presents, most patients are only eligible for transarterial chemoembolization (TACE) or radioembolization (Y90). The purpose of this study is to examine the difference...
Saved in:
| Main Authors: | Kathryn Bress, Patrick Bou-Samra, Cramer J. Kallem, Allan Tsung, Ellie Gammer, David A. Geller, James W. Marsh, Jennifer L. Steel |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-04-01
|
| Series: | Journal of the Egyptian National Cancer Institute |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43046-025-00267-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Health Outcomes and Resource Consumption Analysis of Radioembolization with Y90 Glass Microspheres (TARE-Y90) Versus Transarterial Chemoembolization with Irinotecan (DEBIRI) in Patients with Liver Metastases from Colorectal Cancer in Spain
by: Juan José Ciampi-Dopazo, et al.
Published: (2025-03-01) -
Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis
by: Wenxiao Lu, et al.
Published: (2025-01-01) -
Predictors of Hepatic Decompensation after Yttrium90 Transarterial Radioembolization—Optimizing Patient Selection
by: Amelia Wong, et al.
Published: (2024-08-01) -
Transarterial chemoembolization with insertion of radioactive seeds for hepatocellular carcinoma
by: You-Bin Wang, et al.
Published: (2023-09-01) -
Transarterial chemoembolization for patients with metastatic uveal melanoma in the liver
by: B. I. Dolgushin, et al.
Published: (2016-09-01)